New Generation CAR T-Cells For Cancer Therapy

Feb 6, 2018
Author: 
Linda Quattrin

With CAR T-cell therapy one of the promising technologies emerging in targeted cancer treatment, University of Toronto scientists have taken a step forward in improving the potential effectiveness of this therapeutic approach.

Naoto Hirano - 1

In a paper published this week in Nature Medicine, U of T immunology professor Naoto Hirano – working with colleagues at University Health Network (UHN) and Takara Bio in Japan – outlines a novel method for production of these “living drugs”. The team’s new generation CAR T-cells multiply and remain viable as living cells over a longer period, and show greater effectiveness in fighting specific tumours in immune-deficient mice with human-derived cancer.

“We are hopeful that this technique can move forward with further study to improve the beneficial effects of CAR T-cell therapy for patients,” said Prof. Hirano, a hematologist and oncologist, who is an Associate Professor of Medicine in the Department of Immunology at U of T, and Senior Scientist at Princess Margaret Cancer Centre, UHN. “The benefits of this targeted cancer therapy are very promising, if we can refine our laboratory constructs to optimize their therapeutic effect and minimize any unexpected consequences.”

CAR T-cell therapy was approved by the U.S. Food and Drug Administration in 2017 for the treatment of certain leukemias and lymphomas. The approach involves taking T cells (a type of immune cell) from a patient’s blood and changing them in the laboratory to target that patient’s specific cancer cells. The lab adds a gene for a special receptor called a chimeric antigen receptor (CAR) into the T cells, then grows millions of those CAR T cells, which are then given to the patient by infusion.

While the treatment is very effective in killing specific cancer cells, some patients have experienced serious side effects, such as very high fevers and dangerously low blood pressure, especially as the CAR T-cells multiply in the body in the days after treatment. That’s why scientists are continuing to refine this powerful anti-tumour approach.

Prof. Hirano’s new-generation CAR design can be used in any CAR T-cell, independent of the specific tumour it targets. UHN has filed a patent application related to this study on which Prof. Hirano is the lead inventor. Funding for this research was provided by a number of sources, including the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research, BioCanRX Catalyst Program, the Princess Margaret Cancer Foundation and others. The study was partly sponsored by Takara Bio, Inc.

Sep 11 Cy Frank Legacy Lectureship: Professor Dame Sally Davies
Lecture | 4:30pm–6:00pm
Sep 14 Introduction to Intellectual Property and Entrepreneurship for Biotherapeutic Scientists
Workshop/Seminar | 8:30am–4:00pm
Sep 14 Cardio-Rheumatology Scientific Day
Symposium | 9:30am–2:00pm
Sep 28 Multi-disciplinary Gynecologic Oncology Annual Lecture Series (MyGOALS)
Lecture | 7:30am–4:45pm
Sep 28 MyGOALS – Multi-disciplinary Gynecologic Oncology Annual Lecture Series
Lecture | 7:30am–4:45pm
Sep 29 Frontiers in IBD and Maternal Care Conference
Conference | 8:00am–5:00pm
Oct 16 – Jun 18
CPD Foundations
Workshop/Seminar | 12:00pm–1:30pm

Tweets

UofT Medicine
@uoftmedicine
RT : 8 years ago today, I wrote my . I remember my parents picking me up after the exam, going to the grocery store… https://t.co/yLn5Bp69Lw
UofT Medicine
@uoftmedicine
MD students from the Class of 2T2 receive their stethoscopes & officially join the family!… https://t.co/gRt4ytYEoS

UofTMed Magazine

The Humour issue. Is laughter really the best medicine?

Sign up for your free digital copy.
Back to Top